(Q53565927)

15 May 2018

title

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. (English)

1 reference

15 May 2018

author name string

Vlahakis SR

1

1 reference

15 May 2018

Bren GD

2

1 reference

15 May 2018

Algeciras-Schimnich A

3

1 reference

15 May 2018

Trushin SA

4

1 reference

15 May 2018

Schnepple DJ

5

1 reference

15 May 2018

Badley AD

6

1 reference

15 May 2018

language of work or name

English

0 references

publication date

14 March 2007

1 reference

15 May 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

15 May 2018

volume

82

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

page(s)

294-299

1 reference

15 May 2018

The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

In vitro and in vivo effects of HIV protease inhibitors on apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Atazanavir: A novel once-daily protease inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Emerging anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

HIV-1 fitness and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

The independent effect of drug resistance on T cell activation in HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Atazanavir: improving the HIV protease inhibitor class

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Peptidomimetic inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100140

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100140

1 reference

15 May 2018

1 reference

15 May 2018